Adopted Trials - Lung (nsclc)
Acronym: MAGE 3
Full Title
A Phase I/II study to assess the safety and immunogenicity of recMAGE-A3+AS15 cancer immunotherapeutic given as adjuvant therapy, with or without adjuvant chemo(-radio)therapy, to patients with MAGE-A3-positive Non-Small Cell Lung cancer (stage IB, II or III)
Treatment: Immunological (immunotherapy & gene therapy)
Phase: 1/2
Current status: Open to recruitment
Chief Investigator: Prof Nicholas Thatcher
Type of trial: Early Phase
Website: Protocol Summary
